This morning in partnership with SUFU, we released the 2025 amendment to the Microhematuria (MH) Guideline. This guideline provides a clinical framework for the diagnosis, evaluation and follow-up of MH. Click the link for the full guideline 👉 bit.ly/4ki85gQ

sciencedirect.com/science/articl… Our effort

📰👀Finger test ‘has no role in diagnosing prostate cancer today’ We, alongside Prostate Cancer UK, have united in calling for an end to the routine use of the digital rectal examination, with it no longer being a useful test for #ProstateCancer Via The Times and The Sunday Times: thetimes.com/uk/healthcare/…

बिरामीको चाप बढेपछि बीपी क्यान्सर अस्पतालमा नयाँ फार्मेसी #Nagariknews nagariknews.nagariknetwork.com/social-affairs…

🚨 NEW #PlatinumOpinion in European Urology by M. J. Roberts, Giorgio Gandaglia et al : 💡 Is extended pelvic lymph node dissection (ePLND) still justified in prostate cancer? 📉 No oncologic benefit in RCTs ⚠️ Up to 20% complication rate 🧬 PSMA PET reshapes staging 🔄 2024 EAU

🚨Prostatitis: A review🚨 💡Prostatitis, especially the chronic forms, can be some of the toughest things to treat. 📙Excellent update in JAMA on the latest approaches 👏 Minh Pham, MD Urology@UNC NM Urology 🔗shorturl.at/U8RRA

We’re all excited to see the data and hopeful , but there’s real concern about starting with EV/P upfront and having no better or equivalent option if recurrence happens later ❗️Yes, fewer recurrences mean less need down the line but it’s sometimes not that straightforward

हाम्रा भाइ हरु लाई दुर्गा प्रसाईं ले राजनैतिक फोहोरी गेम खेल्देछ।साच्चै राजनीति चाइ फोहोरी नै खेल हो।

बर्तमान सरकार हत्यारा हो 😡

दलको दल दलबाट मुक्त होऔं !

🚨23 years of PSA screening in NEJM 🚨 👉ERSPC RCT of >162k patients 📅Median 23 year f/u PSA screening lead to... 📉 #prostatecancer mortality by 13% ✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa 📉Risk of advanced PCa by 34% ⭐️Benefit

The ARASAFE trial Presented at #ESMO25 3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC cslide.ctimeetingtech.com/esmo2025/atten… The phase 3 ARASAFE trial (NCT05676203) compared standard docetaxel💊 75 mg/m² every 3 weeks

New #MetaAnalysis on metastatic hormone-sensitive #ProstateCancer (mHSPC): 👍Among 12,668 pts, triplet therapy (ARPI + Docetaxel + ADT) improves OS in synchronous high-volume disease. 👍For all other subgroups, ARPI + ADT is best. 👎No role for Docetaxel + ADT alone.

Hot off the “factory”! World’s FIRST WIRELESS URS. Yes it’s here ! No more cables!! Ps - I have no COI #Endoinnovation Michigan Urology

This article reveals that PSMA PET scans can miss aggressive prostate cancers. Up to 40% of patients with no uptake pattern had intraductal carcinoma (IDC-P), a high-risk subtype. Absence of uptake does not mean low-risk disease.  🔗 Click to read more: bit.ly/48sMwFe

⚡️ NEJM - IMvigor011 takes perioperative Bladder Cancer care a step further. ctDNA-guided adjuvant atezolizumab in ctDNA+ pts after cystectomy improved DFS (9.9 vs 4.8 mo) and OS (32.8 vs 21.1 mo) vs placebo, while ctDNA– pts safely avoided adjuvant IO. #bladdercancer

From PSA to Precision: The Future of Prostate Cancer Diagnosis For decades, PSA has been the cornerstone of prostate cancer detection, saving lives, but also driving overdiagnosis and overtreatment. 🚀 The future is multimodal and data-driven. Our recent review highlights how

Now online! Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al. Thank you to the authors for choosing #EUO to publish your

सस्मित जी त मेरो कम्पनी मै काम गर्नु भएको मान्छे हो। उहाँले धेरै अगाडि नै प्यान लिनु भएको हो। सार्वजनिक गरिने कागजमा संवेदनशील व्यक्तिगत विवरण नराखेको राम्रै कुरा पनि हो! नभए त हामिहरु लाई नागरिकता त छ्याप छ्यापछ्याप्ती सामाजिक सञ्जालमा राख्ने बानी छ!

Johns Hopkins now offers TULSA commercially for intermediate-risk localized prostate cancer. TACT trial showed 65% negative biopsies at 1 year with superior preservation of erectile and urinary function vs traditional therapies. Learn more: hopkinsmedicine.org/news/articles/…